Oppenheimer Starts PolyPid Ltd. (PYPD) at Outperform

Oppenheimer analyst Lee Sulewski initiates coverage on PolyPid Ltd. (NASDAQ: PYPD) with a Outperform rating and a price target of $10.00.

The analyst comments "We initiate coverage of PolyPid at Outperform with a $10 PT. At an EV of ~$100M, investors get D-PLEX100, a locally applied, 30-day Doxycycline depot that cut surgical site infections by ~60% in the sub-group Ph3 study and is under FDA Priority Review with a November 28 PDUFA date. Partner Azurity will commercialize in the US and Canada with PYPD earning tiered mid-teen to mid-20s royalties plus a transfer price on every vial. We expect a measured hospital launch in early 2027, with potential NTAP reimbursement easing budget hurdles from 4Q27. Our base case includes only colorectal procedures with incisions >20cm, leaving broader labeling, Europe, and Kynatrix platform as upside. We see CMC and FDA inspection as the key remaining risk, with answers due within weeks."

For an analyst ratings summary and ratings history on PolyPid Ltd. click here. For more ratings news on PolyPid Ltd. click here.

Shares of PolyPid Ltd. closed at $5.29 yesterday.

You May Also Be Interested In

• Roth/MKM Starts Dianthus Therapeutics (DNTH) at Buy
• Take-Two Interactive (TTWO) PT Lowered to $330 at BofA Securities, 'We recommend being long TTWO through the GTA 6 launch'
• Keefe, Bruyette & Woods Downgrades Bank of Hawaii (BOH) to Market Perform, 'Risk/Reward More Balanced in the Current Backdrop'